ArticleCancer research communications2026
A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
Article in Cancer research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03513211 (A Phase I/II Study of Hydroxychloroquine and Itraconazole as Therapy for Men With Androgen Normalised Prostate Cancer), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I/II Study of Hydroxychloroquine and Itraconazole as Therapy for Men With Androgen Normalised Prostate Cancer
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
purposeBiochemical recurrence (BCR) of prostate cancer presents a clinical challenge with limited systemic treatment options beyond androgen deprivation therapy (ADT), which carries significant morbidity. Preclinical data suggest that lysosomal homeostasis, including cholesterol trafficking and pH regulation, is a therapeutic vulnerability in hormone-dependent cancers. We therefore conducted HITMAN-PC, a phase I trial evaluating suba-itraconazole (SI) and hydroxychloroquine (HCQ) in men with BCR. PATIENTS AND
methodsThe synergy of SI and HCQ was validated in hormone-sensitive and castration-resistant prostate cancer cell lines. The HITMAN-PC trial (NCT03513211) then used a rolling-six design to establish the maximum tolerated dose (MTD) and recommended phase II dose of HCQ with a fixed SI dosage (150 mg twice daily). Secondary endpoints included safety, PSA kinetics [PSA progression-free survival (PFS) and time to ADT], and exploratory pharmacokinetic and lipidomic profiling.
resultsItraconazole showed dose-dependent cytotoxicity, with synergy in LNCaP-derived hormone-sensitive and -resistant lines. Eleven patients were enrolled. Two dose-limiting toxicities at HCQ 600 mg twice daily (grade 3 diarrhea and alanine aminotransferase elevation) defined this level as the MTD with SI 150 mg twice daily. Common adverse events were hypertension, QTc prolongation, diarrhea, and nausea; no grade 4 events occurred. No PSA declines ≥50% were observed although most patients achieved PSA stabilization. The median PSA-PFS, time to ADT, and metastasis-free survival were 5.5, 14.3, and 15.9 months, respectively. Lipidomic profiling revealed 240 treatment-associated lipid changes, with sphingomyelin and triacylglycerol species correlating with PSA-PFS.
conclusionsDespite limited clinical activity overall, the identified lipidomic signatures provide proof of concept for using plasma lipidomics to monitor pharmacodynamic activity in future metabolism-targeted trials. SIGNIFICANCE: This study established a safe dose for HCQ and SI but found limited clinical efficacy in prostate cancer. Its significance lies in providing proof of biology that this combination alters systemic lipid metabolism. We identified specific plasma lipid species that correlate with clinical outcomes, highlighting the power of embedded biomarker analysis to generate valuable mechanistic insights and candidate biomarkers, even in the absence of a strong clinical response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.